OpenURL Connection Search

Select item for more details and to access through your institution.

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition.
Published in:
Oncogene, 2010, v. 29, n. 16, p. 2325, doi. 10.1038/onc.2009.510
By:
- Santo, L.;
- Vallet, S.;
- Hideshima, T.;
- Cirstea, D.;
- Ikeda, H.;
- Pozzi, S.;
- Patel, K.;
- Okawa, Y.;
- Gorgun, G.;
- Perrone, G.;
- Calabrese, E.;
- Yule, M.;
- Squires, M.;
- Ladetto, M.;
- Boccadoro, M.;
- Richardson, P. G.;
- Munshi, N. C.;
- Anderson, K. C.;
- Raje, N.
Publication type:
Article
Extracorporeal photopheresis in chronic graft-versus-host disease.
Published in:
Bone Marrow Transplantation, 2002, v. 29, n. 9, p. 719, doi. 10.1038/sj.bmt.1703529
By:
- Foss, FM;
- Gorgun, G;
- Miller, KB
Publication type:
Article
A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease.
Published in:
Bone Marrow Transplantation, 2004, v. 33, n. 9, p. 881, doi. 10.1038/sj.bmt.1704454
By:
- Roberts, T. F.;
- Chan, G.;
- Schenkein, D. P.;
- Lawrence, D.;
- Sprague, K.;
- Gorgun, G.;
- Relias, V.;
- Grodman, H.;
- Mahajan, A.;
- Foss, F. M.;
- Miller, K. B.
Publication type:
Article
Idiopathic hypereosinophilic syndrome: a case report.
Published in:
2011
By:
- Köse S;
- Cavdar G;
- Gözaydin a;
- Yavas S;
- Görgün G
Publication type:
Journal Article
Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma.
Published in:
Leukemia (08876924), 2015, v. 29, n. 9, p. 1918, doi. 10.1038/leu.2015.83
By:
- Kikuchi, S;
- Suzuki, R;
- Ohguchi, H;
- Yoshida, Y;
- Lu, D;
- Cottini, F;
- Jakubikova, J;
- Bianchi, G;
- Harada, T;
- Gorgun, G;
- Tai, Y-T;
- Richardson, P G;
- Hideshima, T;
- Anderson, K C
Publication type:
Article
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
Published in:
2015
By:
- Suzuki, R;
- Hideshima, T;
- Mimura, N;
- Minami, J;
- Ohguchi, H;
- Kikuchi, S;
- Yoshida, Y;
- Gorgun, G;
- Cirstea, D;
- Cottini, F;
- Jakubikova, J;
- Tai, Y-T;
- Chauhan, D;
- Richardson, P G;
- Munshi, N C;
- Utsugi, T;
- Anderson, K C
Publication type:
Letter
Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.
Published in:
Leukemia (08876924), 2015, v. 29, n. 2, p. 510, doi. 10.1038/leu.2014.300
By:
- Suzuki, R;
- Hideshima, T;
- Mimura, N;
- Minami, J;
- Ohguchi, H;
- Kikuchi, S;
- Yoshida, Y;
- Gorgun, G;
- Cirstea, D;
- Cottini, F;
- Jakubikova, J;
- Tai, Y-T;
- Chauhan, D;
- Richardson, P G;
- Munshi, N C;
- Utsugi, T;
- Anderson, K C
Publication type:
Article
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.
Published in:
Leukemia (08876924), 2014, v. 28, n. 3, p. 680, doi. 10.1038/leu.2013.231
By:
- Minami, J;
- Suzuki, R;
- Mazitschek, R;
- Gorgun, G;
- Ghosh, B;
- Cirstea, D;
- Hu, Y;
- Mimura, N;
- Ohguchi, H;
- Cottini, F;
- Jakubikova, J;
- Munshi, N C;
- Haggarty, S J;
- Richardson, P G;
- Hideshima, T;
- Anderson, K C
Publication type:
Article
Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors.
Published in:
Leukemia (08876924), 2014, v. 28, n. 2, p. 457, doi. 10.1038/leu.2013.301
By:
- Hideshima, T;
- Mazitschek, R;
- Santo, L;
- Mimura, N;
- Gorgun, G;
- Richardson, P G;
- Raje, N;
- Anderson, K C
Publication type:
Article
Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.
Published in:
Leukemia (08876924), 2013, v. 27, n. 12, p. 2366, doi. 10.1038/leu.2013.194
By:
- Cirstea, D;
- Hideshima, T;
- Santo, L;
- Eda, H;
- Mishima, Y;
- Nemani, N;
- Hu, Y;
- Mimura, N;
- Cottini, F;
- Gorgun, G;
- Ohguchi, H;
- Suzuki, R;
- Loferer, H;
- Munshi, N C;
- Anderson, K C;
- Raje, N
Publication type:
Article
Ascorbic acid inhibits antitumor activity of bortezomib in vivo.
Published in:
Leukemia (08876924), 2009, v. 23, n. 9, p. 1679, doi. 10.1038/leu.2009.83
By:
- Perrone, G.;
- Hideshima, T.;
- Ikeda, H.;
- Okawa, Y.;
- Calabrese, E.;
- Gorgun, G.;
- Santo, L.;
- Cirstea, D.;
- Raje, N.;
- Chauhan, D.;
- Baccarani, M.;
- Cavo, M.;
- Anderson, K. C.
Publication type:
Article
A phase II, open‐label, multicenter study of capivasertib, a potent, oral pan‐AKT inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma (CAPITAL).
Published in:
Hematological Oncology, 2023, v. 41, p. 562, doi. 10.1002/hon.3164_421
By:
- Hodson, D.;
- Shouse, G.;
- Shin, H.;
- Salar, A.;
- Bobillo, S.;
- Ribrag, V.;
- Macpherson, N.;
- Cordoba, R.;
- Kim, J. S.;
- Radford, J.;
- Guidez, S.;
- Herrera, A. F.;
- Morchhauser, F.;
- Johnson, D.;
- Izuzquiza, M.;
- Sambamurthy, N.;
- Forcina, A.;
- Gorgun, G.;
- Chen, R.;
- Younes, A.
Publication type:
Article

Found: 12